Volume 90 Issue 33 | p. 17 | Concentrates
Issue Date: August 13, 2012

Novartis, Penn In Immunotherapy Pact

Department: Business
Keywords: pharmaceuticals, industry-academic alliances, immunotherapy

Novartis has teamed with the University of Pennsylvania to bring chimeric antigen receptor (CAR) immunotherapies for the treatment of cancer to market. Penn’s CAR technology recodes a patient’s own T cells to express proteins found on the patient’s tumor. When reintroduced into the patient’s bloodstream, those engineered T cells can bind to and kill tumor cells. Novartis gains access to CART-19, an immunotherapy that has shown promise in a . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society